 Stuart Sprague
Concepts (467)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperparathyroidism, Secondary | 31 | 2022 | 71 | 8.860 |
Why?
| | Renal Insufficiency, Chronic | 30 | 2021 | 293 | 8.080 |
Why?
| | Renal Dialysis | 45 | 2022 | 362 | 7.110 |
Why?
| | Hyperphosphatemia | 17 | 2022 | 19 | 6.510 |
Why?
| | Ferric Compounds | 13 | 2022 | 36 | 5.840 |
Why?
| | Sucrose | 12 | 2022 | 60 | 5.710 |
Why?
| | Kidney Failure, Chronic | 40 | 2022 | 500 | 5.660 |
Why?
| | Parathyroid Hormone | 44 | 2020 | 209 | 5.030 |
Why?
| | Vitamin D Deficiency | 11 | 2020 | 100 | 3.950 |
Why?
| | Ergocalciferols | 15 | 2020 | 38 | 3.770 |
Why?
| | Vitamin D | 17 | 2020 | 252 | 3.740 |
Why?
| | Phosphorus | 22 | 2022 | 121 | 3.410 |
Why?
| | Bone and Bones | 19 | 2015 | 254 | 3.050 |
Why?
| | Chelating Agents | 10 | 2021 | 69 | 2.880 |
Why?
| | Bone Diseases, Metabolic | 9 | 2018 | 33 | 2.790 |
Why?
| | Kidney Diseases | 17 | 2010 | 407 | 2.780 |
Why?
| | Kidney Transplantation | 14 | 2020 | 792 | 2.770 |
Why?
| | Calcium | 31 | 2016 | 1122 | 2.670 |
Why?
| | Calcitriol | 15 | 2020 | 174 | 2.660 |
Why?
| | Vitamins | 6 | 2016 | 71 | 2.230 |
Why?
| | Phosphates | 10 | 2022 | 154 | 2.160 |
Why?
| | Bone Diseases | 7 | 2020 | 54 | 2.110 |
Why?
| | beta 2-Microglobulin | 11 | 2008 | 27 | 1.800 |
Why?
| | Bone Density | 17 | 2018 | 203 | 1.790 |
Why?
| | Glomerular Filtration Rate | 14 | 2021 | 373 | 1.750 |
Why?
| | Calcifediol | 4 | 2019 | 21 | 1.650 |
Why?
| | Fibroblast Growth Factors | 7 | 2020 | 78 | 1.650 |
Why?
| | Minerals | 3 | 2018 | 19 | 1.550 |
Why?
| | Lanthanum | 6 | 2020 | 15 | 1.440 |
Why?
| | Drug Combinations | 12 | 2022 | 223 | 1.440 |
Why?
| | Humans | 129 | 2022 | 79512 | 1.300 |
Why?
| | Amyloidosis | 8 | 2008 | 80 | 1.230 |
Why?
| | Naphthalenes | 5 | 2010 | 46 | 1.220 |
Why?
| | Calciphylaxis | 2 | 2016 | 5 | 1.140 |
Why?
| | Iron | 4 | 2022 | 152 | 1.110 |
Why?
| | Middle Aged | 52 | 2021 | 23948 | 1.020 |
Why?
| | Receptors, Calcitriol | 4 | 2016 | 129 | 1.020 |
Why?
| | Osteoporosis | 7 | 2011 | 119 | 1.020 |
Why?
| | Calcimimetic Agents | 4 | 2020 | 7 | 0.980 |
Why?
| | Aged | 41 | 2021 | 17394 | 0.970 |
Why?
| | Peritoneal Dialysis | 6 | 2017 | 32 | 0.960 |
Why?
| | Male | 63 | 2021 | 39419 | 0.940 |
Why?
| | Calcium Channel Agonists | 5 | 2007 | 13 | 0.930 |
Why?
| | Isoquinolines | 1 | 2021 | 70 | 0.870 |
Why?
| | Intestinal Absorption | 1 | 2021 | 122 | 0.860 |
Why?
| | Female | 61 | 2021 | 42244 | 0.860 |
Why?
| | Parathyroidectomy | 3 | 2022 | 73 | 0.840 |
Why?
| | Iron Overload | 1 | 2020 | 5 | 0.830 |
Why?
| | Bone Resorption | 5 | 2008 | 42 | 0.830 |
Why?
| | Kidney Cortex | 2 | 2019 | 32 | 0.800 |
Why?
| | Fractures, Bone | 5 | 2007 | 119 | 0.790 |
Why?
| | Treatment Outcome | 20 | 2019 | 7469 | 0.770 |
Why?
| | Intestine, Small | 1 | 2021 | 290 | 0.760 |
Why?
| | Anemia | 1 | 2020 | 124 | 0.750 |
Why?
| | Sulfonamides | 1 | 2021 | 295 | 0.750 |
Why?
| | Polyamines | 3 | 2014 | 31 | 0.750 |
Why?
| | Kidney Tubules | 1 | 2019 | 95 | 0.710 |
Why?
| | Femoral Neck Fractures | 1 | 2018 | 7 | 0.700 |
Why?
| | Chronic Disease | 12 | 2010 | 932 | 0.680 |
Why?
| | Fracture Fixation, Internal | 1 | 2018 | 55 | 0.670 |
Why?
| | Hypercalcemia | 5 | 2014 | 56 | 0.670 |
Why?
| | Bone Remodeling | 3 | 2015 | 23 | 0.670 |
Why?
| | Kidney | 9 | 2022 | 1169 | 0.640 |
Why?
| | Aluminum | 12 | 1995 | 20 | 0.630 |
Why?
| | Hyperparathyroidism | 1 | 2016 | 67 | 0.630 |
Why?
| | Skull | 9 | 2008 | 238 | 0.620 |
Why?
| | Inflammation | 2 | 2020 | 819 | 0.610 |
Why?
| | Bone Density Conservation Agents | 4 | 2016 | 45 | 0.590 |
Why?
| | Nephrology | 1 | 2016 | 38 | 0.590 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 978 | 0.570 |
Why?
| | Adult | 35 | 2020 | 24525 | 0.570 |
Why?
| | Disease Progression | 9 | 2021 | 1424 | 0.560 |
Why?
| | Double-Blind Method | 10 | 2019 | 1778 | 0.550 |
Why?
| | Calcinosis | 3 | 2013 | 232 | 0.530 |
Why?
| | Skin Ulcer | 1 | 2013 | 25 | 0.510 |
Why?
| | Oxygen | 4 | 2021 | 700 | 0.510 |
Why?
| | Osteoblasts | 4 | 2001 | 94 | 0.500 |
Why?
| | Time Factors | 16 | 2021 | 5143 | 0.500 |
Why?
| | Risk Factors | 13 | 2015 | 5099 | 0.470 |
Why?
| | Osteoclasts | 4 | 2013 | 33 | 0.450 |
Why?
| | Administration, Oral | 5 | 2020 | 686 | 0.440 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 39 | 0.440 |
Why?
| | Osteogenesis | 6 | 2017 | 237 | 0.440 |
Why?
| | Calcification, Physiologic | 3 | 2007 | 33 | 0.420 |
Why?
| | Pain | 1 | 2013 | 353 | 0.420 |
Why?
| | Furosemide | 3 | 2019 | 34 | 0.410 |
Why?
| | Quality of Life | 1 | 2018 | 1342 | 0.410 |
Why?
| | Alkaline Phosphatase | 6 | 2015 | 132 | 0.400 |
Why?
| | Prognosis | 7 | 2018 | 3522 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 5 | 2021 | 3069 | 0.380 |
Why?
| | Oleanolic Acid | 2 | 2019 | 11 | 0.370 |
Why?
| | Creatinine | 4 | 2021 | 330 | 0.370 |
Why?
| | Drug Interactions | 2 | 2021 | 250 | 0.360 |
Why?
| | Medication Adherence | 3 | 2019 | 117 | 0.360 |
Why?
| | Pancreas Transplantation | 3 | 2004 | 103 | 0.350 |
Why?
| | Cyclosporine | 3 | 2004 | 240 | 0.350 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 1367 | 0.350 |
Why?
| | Aged, 80 and over | 10 | 2019 | 6195 | 0.350 |
Why?
| | Animals | 32 | 2021 | 25594 | 0.350 |
Why?
| | Biopsy | 4 | 2009 | 1117 | 0.340 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2020 | 246 | 0.330 |
Why?
| | Protein Kinase C | 2 | 1999 | 270 | 0.320 |
Why?
| | Coronary Artery Disease | 1 | 2011 | 323 | 0.320 |
Why?
| | Hip Fractures | 1 | 2007 | 36 | 0.320 |
Why?
| | Interleukin-6 | 3 | 2008 | 226 | 0.310 |
Why?
| | Metabolic Diseases | 1 | 2007 | 46 | 0.310 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 767 | 0.310 |
Why?
| | Spinal Fractures | 1 | 2007 | 73 | 0.300 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 118 | 0.290 |
Why?
| | Severity of Illness Index | 6 | 2021 | 1686 | 0.290 |
Why?
| | Practice Guidelines as Topic | 5 | 2019 | 1030 | 0.280 |
Why?
| | Prospective Studies | 8 | 2022 | 3870 | 0.270 |
Why?
| | Canada | 3 | 2015 | 194 | 0.260 |
Why?
| | Hospitalization | 2 | 2007 | 748 | 0.260 |
Why?
| | Azathioprine | 1 | 2004 | 122 | 0.250 |
Why?
| | United States | 9 | 2022 | 6050 | 0.250 |
Why?
| | Biological Transport | 2 | 2021 | 396 | 0.240 |
Why?
| | Rats | 11 | 2020 | 3921 | 0.240 |
Why?
| | Diabetic Nephropathies | 3 | 2019 | 230 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 2 | 2011 | 2439 | 0.230 |
Why?
| | Niacinamide | 2 | 2020 | 117 | 0.230 |
Why?
| | Interleukin-1 | 2 | 2008 | 73 | 0.230 |
Why?
| | Albuminuria | 2 | 2021 | 143 | 0.230 |
Why?
| | Rats, Sprague-Dawley | 4 | 2020 | 1190 | 0.230 |
Why?
| | Retrospective Studies | 6 | 2022 | 7386 | 0.220 |
Why?
| | Glucose | 2 | 2002 | 603 | 0.220 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2007 | 1969 | 0.210 |
Why?
| | Phosphorus, Dietary | 1 | 2020 | 4 | 0.210 |
Why?
| | Kidney Medulla | 1 | 2021 | 78 | 0.210 |
Why?
| | Cholecalciferol | 1 | 2020 | 33 | 0.200 |
Why?
| | Sodium Bicarbonate | 1 | 2019 | 8 | 0.200 |
Why?
| | Tissue Distribution | 2 | 2020 | 277 | 0.200 |
Why?
| | Cognition Disorders | 2 | 1994 | 228 | 0.200 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2019 | 1257 | 0.190 |
Why?
| | Rats, Wistar | 1 | 2020 | 292 | 0.190 |
Why?
| | Bone Substitutes | 1 | 1999 | 9 | 0.190 |
Why?
| | Mice | 13 | 2017 | 10710 | 0.190 |
Why?
| | Biomedical Engineering | 1 | 1999 | 19 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2017 | 677 | 0.190 |
Why?
| | Cytokines | 4 | 2012 | 742 | 0.190 |
Why?
| | Bone Regeneration | 1 | 1999 | 51 | 0.180 |
Why?
| | Waist Circumference | 1 | 2018 | 20 | 0.180 |
Why?
| | Absorbable Implants | 1 | 1999 | 35 | 0.180 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 134 | 0.180 |
Why?
| | Russia | 2 | 2015 | 24 | 0.180 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2020 | 132 | 0.180 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 742 | 0.180 |
Why?
| | Drug Therapy, Combination | 3 | 2020 | 902 | 0.180 |
Why?
| | Australia | 2 | 2015 | 90 | 0.180 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1149 | 0.180 |
Why?
| | Government Regulation | 1 | 2018 | 50 | 0.180 |
Why?
| | Kinetics | 2 | 2020 | 1524 | 0.170 |
Why?
| | Cell Hypoxia | 1 | 2019 | 160 | 0.170 |
Why?
| | Oxygen Consumption | 1 | 2019 | 234 | 0.170 |
Why?
| | Acid Phosphatase | 3 | 2008 | 34 | 0.170 |
Why?
| | Mice, Inbred Strains | 4 | 2008 | 310 | 0.170 |
Why?
| | Kidney Function Tests | 1 | 2018 | 125 | 0.170 |
Why?
| | Risk Assessment | 3 | 2019 | 2158 | 0.170 |
Why?
| | Case-Control Studies | 4 | 2019 | 1722 | 0.170 |
Why?
| | Disability Evaluation | 1 | 2018 | 120 | 0.170 |
Why?
| | Arthritis, Experimental | 1 | 2017 | 24 | 0.160 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 2016 | 2 | 0.160 |
Why?
| | Body Weight | 1 | 2018 | 457 | 0.160 |
Why?
| | International Agencies | 1 | 2016 | 34 | 0.160 |
Why?
| | Granzymes | 1 | 2017 | 90 | 0.160 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2019 | 320 | 0.160 |
Why?
| | Blood Chemical Analysis | 1 | 2016 | 44 | 0.160 |
Why?
| | Osteocalcin | 3 | 2001 | 26 | 0.160 |
Why?
| | Biomarkers, Pharmacological | 1 | 2016 | 22 | 0.160 |
Why?
| | Pain Measurement | 1 | 2018 | 292 | 0.160 |
Why?
| | Organ Culture Techniques | 5 | 2000 | 132 | 0.150 |
Why?
| | Magnetic Resonance Angiography | 1 | 2019 | 248 | 0.150 |
Why?
| | Guideline Adherence | 1 | 2018 | 215 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2019 | 2570 | 0.150 |
Why?
| | Extracorporeal Circulation | 2 | 2013 | 23 | 0.150 |
Why?
| | Immunoassay | 2 | 2016 | 87 | 0.150 |
Why?
| | Logistic Models | 2 | 2020 | 1113 | 0.150 |
Why?
| | Vascular Calcification | 1 | 2016 | 38 | 0.150 |
Why?
| | Arthritis, Rheumatoid | 1 | 2017 | 152 | 0.150 |
Why?
| | Organ Transplantation | 1 | 1999 | 249 | 0.140 |
Why?
| | Collagen Type I | 1 | 2015 | 62 | 0.140 |
Why?
| | Blood Glucose | 2 | 2018 | 850 | 0.140 |
Why?
| | Least-Squares Analysis | 1 | 2015 | 46 | 0.140 |
Why?
| | Prostaglandins | 1 | 1995 | 43 | 0.140 |
Why?
| | Incidence | 2 | 2014 | 1528 | 0.140 |
Why?
| | Acidosis, Respiratory | 1 | 1994 | 7 | 0.140 |
Why?
| | Uremia | 1 | 1994 | 14 | 0.140 |
Why?
| | Radiology | 1 | 2017 | 179 | 0.140 |
Why?
| | Infarction | 1 | 1994 | 23 | 0.140 |
Why?
| | Acidosis | 1 | 1994 | 56 | 0.140 |
Why?
| | Hypocalcemia | 1 | 1994 | 39 | 0.140 |
Why?
| | Nonlinear Dynamics | 1 | 2015 | 88 | 0.140 |
Why?
| | Sex Factors | 2 | 2013 | 1021 | 0.140 |
Why?
| | Parathyroid Glands | 1 | 1994 | 70 | 0.140 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 359 | 0.130 |
Why?
| | Dietary Supplements | 1 | 2015 | 122 | 0.130 |
Why?
| | Sorption Detoxification | 1 | 2013 | 2 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1602 | 0.130 |
Why?
| | Linear Models | 1 | 2015 | 401 | 0.130 |
Why?
| | Brain Diseases | 1 | 1994 | 171 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2015 | 154 | 0.120 |
Why?
| | Hematologic Tests | 1 | 2012 | 12 | 0.120 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1618 | 0.120 |
Why?
| | Colony-Forming Units Assay | 1 | 2012 | 40 | 0.120 |
Why?
| | Serum | 1 | 2012 | 23 | 0.120 |
Why?
| | Serum Amyloid P-Component | 1 | 1992 | 7 | 0.120 |
Why?
| | Diagnostic Tests, Routine | 1 | 2012 | 57 | 0.120 |
Why?
| | Cell Separation | 1 | 2012 | 196 | 0.110 |
Why?
| | Phosphate-Binding Proteins | 2 | 2010 | 9 | 0.110 |
Why?
| | Citric Acid | 2 | 2010 | 38 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2012 | 151 | 0.110 |
Why?
| | Obesity | 1 | 2018 | 907 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2001 | 2787 | 0.110 |
Why?
| | Wound Healing | 1 | 2013 | 334 | 0.110 |
Why?
| | Gene Expression | 3 | 2008 | 1278 | 0.110 |
Why?
| | Nanocomposites | 1 | 2010 | 11 | 0.110 |
Why?
| | Absorptiometry, Photon | 3 | 2010 | 98 | 0.100 |
Why?
| | Deferoxamine | 2 | 1988 | 18 | 0.100 |
Why?
| | Protein-Energy Malnutrition | 1 | 2010 | 5 | 0.100 |
Why?
| | Early Diagnosis | 1 | 2010 | 125 | 0.100 |
Why?
| | African Americans | 1 | 2018 | 1076 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 1991 | 142 | 0.100 |
Why?
| | Models, Biological | 2 | 2008 | 1724 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2012 | 385 | 0.100 |
Why?
| | Alzheimer Disease | 2 | 1991 | 328 | 0.090 |
Why?
| | Age Factors | 4 | 2020 | 1797 | 0.090 |
Why?
| | Cell Line | 3 | 2013 | 2470 | 0.090 |
Why?
| | Cell Division | 2 | 2001 | 703 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2019 | 3553 | 0.090 |
Why?
| | Europe | 1 | 2009 | 293 | 0.090 |
Why?
| | Neuromuscular Diseases | 1 | 1988 | 31 | 0.090 |
Why?
| | Graft Rejection | 2 | 2006 | 1046 | 0.090 |
Why?
| | Receptors, Calcitonin | 1 | 2008 | 4 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2009 | 392 | 0.090 |
Why?
| | RANK Ligand | 1 | 2008 | 8 | 0.090 |
Why?
| | Integrin beta3 | 1 | 2008 | 31 | 0.090 |
Why?
| | Physical Conditioning, Animal | 1 | 2007 | 18 | 0.090 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 63 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 70 | 0.080 |
Why?
| | Cyclic AMP | 2 | 1999 | 266 | 0.080 |
Why?
| | Proteinuria | 1 | 2008 | 108 | 0.080 |
Why?
| | Morbidity | 1 | 2007 | 135 | 0.080 |
Why?
| | Placebos | 1 | 2007 | 218 | 0.080 |
Why?
| | Isoenzymes | 1 | 2008 | 269 | 0.080 |
Why?
| | Myoclonus | 1 | 1986 | 10 | 0.080 |
Why?
| | Animals, Newborn | 3 | 1994 | 520 | 0.080 |
Why?
| | Enzyme Activation | 2 | 1999 | 691 | 0.080 |
Why?
| | Algorithms | 1 | 2015 | 1768 | 0.080 |
Why?
| | Microscopy, Electron, Scanning | 2 | 1999 | 134 | 0.080 |
Why?
| | Patient Selection | 1 | 2010 | 662 | 0.080 |
Why?
| | Capsules | 1 | 2006 | 36 | 0.080 |
Why?
| | Regression Analysis | 3 | 2010 | 588 | 0.080 |
Why?
| | Antibodies | 1 | 2008 | 342 | 0.080 |
Why?
| | Receptors, Calcium-Sensing | 1 | 2005 | 11 | 0.070 |
Why?
| | Down-Regulation | 2 | 2013 | 501 | 0.070 |
Why?
| | Immunosorbent Techniques | 1 | 2005 | 13 | 0.070 |
Why?
| | Adolescent | 3 | 2009 | 8657 | 0.070 |
Why?
| | Dementia | 1 | 1986 | 164 | 0.070 |
Why?
| | Polymers | 2 | 2013 | 187 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 845 | 0.070 |
Why?
| | Patient Satisfaction | 1 | 2008 | 422 | 0.070 |
Why?
| | Radius | 1 | 2004 | 27 | 0.070 |
Why?
| | Femur Neck | 1 | 2004 | 39 | 0.070 |
Why?
| | Terminology as Topic | 1 | 2006 | 214 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1937 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2010 | 2067 | 0.070 |
Why?
| | Cost-Benefit Analysis | 1 | 2007 | 418 | 0.070 |
Why?
| | Seizures | 1 | 1986 | 253 | 0.070 |
Why?
| | Brain Ischemia | 1 | 2007 | 311 | 0.060 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 149 | 0.060 |
Why?
| | Peritoneal Dialysis, Continuous Ambulatory | 1 | 2003 | 13 | 0.060 |
Why?
| | Carpal Tunnel Syndrome | 1 | 2003 | 16 | 0.060 |
Why?
| | Joints | 1 | 2003 | 34 | 0.060 |
Why?
| | Medical Records | 1 | 2004 | 114 | 0.060 |
Why?
| | Membranes, Artificial | 1 | 2003 | 40 | 0.060 |
Why?
| | Protein Denaturation | 1 | 2003 | 105 | 0.060 |
Why?
| | Comorbidity | 1 | 2007 | 907 | 0.060 |
Why?
| | Tacrolimus | 1 | 2004 | 375 | 0.060 |
Why?
| | Glucans | 1 | 2002 | 9 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 441 | 0.060 |
Why?
| | Osteomalacia | 1 | 2001 | 13 | 0.060 |
Why?
| | Glucuronidase | 2 | 1992 | 20 | 0.060 |
Why?
| | Calcitonin | 2 | 1992 | 38 | 0.060 |
Why?
| | Diuretics, Osmotic | 1 | 2001 | 2 | 0.050 |
Why?
| | Anthraquinones | 1 | 2001 | 7 | 0.050 |
Why?
| | Mannitol | 1 | 2001 | 49 | 0.050 |
Why?
| | Coloring Agents | 1 | 2001 | 65 | 0.050 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2000 | 19 | 0.050 |
Why?
| | Sepharose | 2 | 2013 | 14 | 0.050 |
Why?
| | Vitamin B Complex | 1 | 2020 | 21 | 0.050 |
Why?
| | Staurosporine | 1 | 1999 | 32 | 0.050 |
Why?
| | Stroke | 1 | 2007 | 752 | 0.050 |
Why?
| | Early Termination of Clinical Trials | 1 | 2019 | 20 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2000 | 105 | 0.050 |
Why?
| | Polyglycolic Acid | 1 | 1999 | 9 | 0.050 |
Why?
| | Fibrosis | 1 | 2020 | 188 | 0.050 |
Why?
| | Biopolymers | 1 | 1998 | 25 | 0.050 |
Why?
| | Liver Transplantation | 2 | 1999 | 1238 | 0.050 |
Why?
| | Lactic Acid | 1 | 1999 | 84 | 0.050 |
Why?
| | Monte Carlo Method | 1 | 2019 | 182 | 0.040 |
Why?
| | Hematoma | 1 | 1999 | 88 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2019 | 114 | 0.040 |
Why?
| | Pattern Recognition, Automated | 1 | 2019 | 218 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 1998 | 126 | 0.040 |
Why?
| | Rats, Inbred Strains | 2 | 1996 | 314 | 0.040 |
Why?
| | Renal Circulation | 1 | 2018 | 61 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2000 | 337 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 803 | 0.040 |
Why?
| | Spin Labels | 1 | 2018 | 101 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1722 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 653 | 0.040 |
Why?
| | Potassium Channels | 1 | 2000 | 335 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2000 | 1920 | 0.040 |
Why?
| | Pilot Projects | 1 | 2019 | 796 | 0.040 |
Why?
| | Steroids | 1 | 1998 | 165 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 1998 | 273 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 626 | 0.040 |
Why?
| | Translocation, Genetic | 1 | 1996 | 259 | 0.040 |
Why?
| | Acute Kidney Injury | 2 | 1989 | 264 | 0.040 |
Why?
| | Prostaglandin Antagonists | 1 | 1995 | 7 | 0.040 |
Why?
| | Indomethacin | 1 | 1995 | 60 | 0.040 |
Why?
| | Radiography | 2 | 1998 | 804 | 0.030 |
Why?
| | Bicarbonates | 1 | 1994 | 60 | 0.030 |
Why?
| | 3T3 Cells | 1 | 1994 | 94 | 0.030 |
Why?
| | Culture Media | 1 | 1994 | 144 | 0.030 |
Why?
| | Ion Transport | 1 | 1994 | 79 | 0.030 |
Why?
| | Amyloid | 1 | 1995 | 76 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 947 | 0.030 |
Why?
| | Body Mass Index | 1 | 2018 | 740 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2014 | 25 | 0.030 |
Why?
| | Adsorption | 1 | 2013 | 49 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 55 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2013 | 46 | 0.030 |
Why?
| | Sulfones | 1 | 2013 | 51 | 0.030 |
Why?
| | Heart Transplantation | 1 | 1999 | 649 | 0.030 |
Why?
| | Maintenance Chemotherapy | 1 | 2014 | 75 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2016 | 304 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2013 | 60 | 0.030 |
Why?
| | Constipation | 1 | 2014 | 57 | 0.030 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1993 | 34 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 1153 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1994 | 494 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1993 | 181 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1994 | 199 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2014 | 142 | 0.030 |
Why?
| | Diarrhea | 1 | 2014 | 177 | 0.030 |
Why?
| | Neurons | 2 | 2000 | 1471 | 0.030 |
Why?
| | Blood Donors | 1 | 2012 | 25 | 0.030 |
Why?
| | Equipment Design | 1 | 2013 | 400 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 168 | 0.030 |
Why?
| | Hip | 1 | 1992 | 18 | 0.030 |
Why?
| | Cohort Studies | 1 | 1999 | 2561 | 0.030 |
Why?
| | Shoulder | 1 | 1992 | 43 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 1992 | 244 | 0.030 |
Why?
| | Behavior, Animal | 2 | 2007 | 354 | 0.030 |
Why?
| | Chlorides | 2 | 2002 | 105 | 0.030 |
Why?
| | Lysosomes | 1 | 1992 | 108 | 0.030 |
Why?
| | Rabbits | 2 | 2010 | 656 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2013 | 720 | 0.030 |
Why?
| | Hand | 1 | 1992 | 120 | 0.030 |
Why?
| | Absorption | 2 | 2002 | 25 | 0.030 |
Why?
| | Implants, Experimental | 1 | 2010 | 16 | 0.030 |
Why?
| | Durapatite | 1 | 2010 | 30 | 0.030 |
Why?
| | Materials Testing | 1 | 2010 | 90 | 0.030 |
Why?
| | Electroencephalography | 1 | 1994 | 669 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1992 | 455 | 0.020 |
Why?
| | Heart Failure | 1 | 2019 | 1075 | 0.020 |
Why?
| | Reimbursement Mechanisms | 1 | 2010 | 40 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 3052 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 1447 | 0.020 |
Why?
| | DNA | 2 | 1993 | 1246 | 0.020 |
Why?
| | Biocompatible Materials | 1 | 2010 | 184 | 0.020 |
Why?
| | Body Burden | 1 | 1988 | 9 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2010 | 266 | 0.020 |
Why?
| | Sarcoidosis | 1 | 1988 | 67 | 0.020 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 16 | 0.020 |
Why?
| | Collagen Type IV | 1 | 2007 | 23 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2007 | 30 | 0.020 |
Why?
| | Proteins | 1 | 1993 | 751 | 0.020 |
Why?
| | Brain Edema | 1 | 2007 | 51 | 0.020 |
Why?
| | Medicare | 1 | 2010 | 302 | 0.020 |
Why?
| | Capillaries | 1 | 2007 | 89 | 0.020 |
Why?
| | Calcium, Dietary | 1 | 2007 | 60 | 0.020 |
Why?
| | Functional Laterality | 1 | 2007 | 198 | 0.020 |
Why?
| | Tablets | 1 | 2008 | 107 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 931 | 0.020 |
Why?
| | Survival Analysis | 1 | 2010 | 1519 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2246 | 0.020 |
Why?
| | Fluorides | 1 | 1985 | 13 | 0.020 |
Why?
| | Blotting, Western | 1 | 2007 | 777 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 869 | 0.020 |
Why?
| | Sterilization | 1 | 2005 | 7 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1988 | 328 | 0.020 |
Why?
| | Movement | 1 | 2007 | 279 | 0.020 |
Why?
| | Drug Stability | 1 | 2005 | 47 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1989 | 440 | 0.020 |
Why?
| | Immunoglobulin Variable Region | 1 | 2005 | 110 | 0.020 |
Why?
| | RNA | 1 | 2007 | 505 | 0.020 |
Why?
| | Titrimetry | 1 | 2003 | 15 | 0.020 |
Why?
| | Blood | 1 | 2002 | 69 | 0.010 |
Why?
| | Peritoneum | 1 | 2002 | 45 | 0.010 |
Why?
| | Aluminum Compounds | 1 | 1982 | 6 | 0.010 |
Why?
| | Urine | 1 | 2002 | 81 | 0.010 |
Why?
| | Sodium | 1 | 2002 | 330 | 0.010 |
Why?
| | Charybdotoxin | 1 | 2000 | 8 | 0.010 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2000 | 5 | 0.010 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 1 | 2000 | 11 | 0.010 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2000 | 8 | 0.010 |
Why?
| | Haplorhini | 1 | 2000 | 98 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 5701 | 0.010 |
Why?
| | Protein Structure, Quaternary | 1 | 2000 | 101 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2000 | 305 | 0.010 |
Why?
| | Epitopes | 1 | 2000 | 255 | 0.010 |
Why?
| | Electrophysiology | 1 | 2000 | 407 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 1979 | 75 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 651 | 0.010 |
Why?
| | Bone Morphogenetic Protein 2 | 1 | 1998 | 37 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2000 | 440 | 0.010 |
Why?
| | Choristoma | 1 | 1998 | 69 | 0.010 |
Why?
| | Drug Carriers | 1 | 1998 | 82 | 0.010 |
Why?
| | Fetus | 1 | 1979 | 213 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1998 | 127 | 0.010 |
Why?
| | Ion Channel Gating | 1 | 2000 | 320 | 0.010 |
Why?
| | Insulin | 1 | 2002 | 1126 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 827 | 0.010 |
Why?
| | Peptides | 1 | 2000 | 619 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1998 | 1015 | 0.010 |
Why?
| | Cations, Monovalent | 1 | 1995 | 5 | 0.010 |
Why?
| | Cations, Divalent | 1 | 1995 | 38 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2077 | 0.010 |
Why?
| | Surface Properties | 1 | 1995 | 124 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 823 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1998 | 972 | 0.010 |
Why?
| | Platelet Transfusion | 1 | 1995 | 14 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 1995 | 175 | 0.010 |
Why?
| | Citrates | 1 | 1995 | 28 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 3050 | 0.010 |
Why?
| | Intraoperative Care | 1 | 1995 | 80 | 0.010 |
Why?
| | Erythrocyte Transfusion | 1 | 1995 | 53 | 0.010 |
Why?
| | Prevalence | 1 | 1998 | 1163 | 0.010 |
Why?
| | Water Supply | 2 | 1985 | 60 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1995 | 899 | 0.010 |
Why?
| | Child | 1 | 2004 | 6481 | 0.010 |
Why?
| | Anticoagulants | 1 | 1995 | 380 | 0.010 |
Why?
| | Discriminant Analysis | 1 | 1989 | 64 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1995 | 2249 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1988 | 64 | 0.010 |
Why?
| | Pregnancy | 2 | 1988 | 2670 | 0.010 |
Why?
| | Computers | 1 | 1985 | 105 | 0.000 |
Why?
| | Brain | 2 | 1985 | 1998 | 0.000 |
Why?
| | Binding Sites | 1 | 1985 | 1083 | 0.000 |
Why?
| | Extinction, Psychological | 1 | 1982 | 14 | 0.000 |
Why?
| | Avoidance Learning | 1 | 1982 | 16 | 0.000 |
Why?
| | Rats, Inbred F344 | 1 | 1982 | 158 | 0.000 |
Why?
| | Michigan | 1 | 1981 | 48 | 0.000 |
Why?
| | Motor Skills | 1 | 1982 | 71 | 0.000 |
Why?
| | Brain Chemistry | 1 | 1981 | 113 | 0.000 |
Why?
| | Dogs | 1 | 1981 | 694 | 0.000 |
Why?
| | Teratogens | 1 | 1979 | 12 | 0.000 |
Why?
| | Fetal Death | 1 | 1979 | 59 | 0.000 |
Why?
| | Motor Activity | 1 | 1982 | 321 | 0.000 |
Why?
| | Drug Synergism | 1 | 1979 | 304 | 0.000 |
Why?
| | Neutron Activation Analysis | 1 | 1978 | 2 | 0.000 |
Why?
| | Spectrophotometry, Atomic | 1 | 1978 | 12 | 0.000 |
Why?
| | Gestational Age | 1 | 1979 | 294 | 0.000 |
Why?
| | Diet | 1 | 1980 | 427 | 0.000 |
Why?
| | Mental Disorders | 1 | 1978 | 360 | 0.000 |
Why?
|
|
Sprague's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|